AMGN Amgen Inc

Price (delayed)

$211.8

Market cap

$120.27B

P/E Ratio

21.39

Dividend/share

$6.88

EPS

$9.9

Enterprise value

$146.42B

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980. ...

Highlights
The revenue has grown by 4.9% year-on-year
The debt has declined by 4.2% year-on-year
The P/E is 13% below the 5-year quarterly average of 24.8 but 2.5% above the last 4 quarters average of 21.0
AMGN's quick ratio is down by 46% year-on-year and by 26% since the previous quarter
Amgen's equity has decreased by 23% YoY and by 12% from the previous quarter

Key stats

What are the main financial stats of AMGN
Market
Shares outstanding
567.85M
Market cap
$120.27B
Enterprise value
$146.42B
Valuations
Price to earnings (P/E)
21.39
Price to book (P/B)
14.76
Price to sales (P/S)
4.76
EV/EBIT
19.06
EV/EBITDA
13.13
EV/Sales
5.75
Earnings
Revenue
$25.48B
EBIT
$7.68B
EBITDA
$11.15B
Free cash flow
$8.9B
Per share
EPS
$9.9
Free cash flow per share
$15.53
Book value per share
$14.35
Revenue per share
$44.47
TBVPS
$51.99
Balance sheet
Total assets
$59.77B
Total liabilities
$51.53B
Debt
$32.78B
Equity
$8.25B
Working capital
$4.51B
Liquidity
Debt to equity
3.98
Current ratio
1.31
Quick ratio
0.86
Net debt/EBITDA
2.34
Margins
EBITDA margin
43.8%
Gross margin
75.3%
Net margin
22.5%
Operating margin
29.1%
Efficiency
Return on assets
9.2%
Return on equity
60.6%
Return on invested capital
16.9%
Return on capital employed
17%
Return on sales
30.2%
Dividend
Dividend yield
3.25%
DPS
$6.88
Payout ratio
69.5%

AMGN stock price

How has the Amgen stock price performed over time
Intraday
-0.61%
1 week
-1.65%
1 month
-4.93%
1 year
-14.26%
YTD
-7.88%
QTD
-13.11%

Financial performance

How have Amgen's revenue and profit performed over time
Revenue
$25.48B
Gross profit
$19.2B
Operating income
$7.42B
Net income
$5.75B
Gross margin
75.3%
Net margin
22.5%
The net margin has declined by 25% year-on-year and by 20% since the previous quarter
The company's operating margin fell by 23% YoY and by 18% QoQ
The net income has contracted by 21% YoY and by 19% from the previous quarter
AMGN's operating income is down by 19% year-on-year and by 17% since the previous quarter

Growth

What is Amgen's growth rate over time

Valuation

What is Amgen stock price valuation
P/E
21.39
P/B
14.76
P/S
4.76
EV/EBIT
19.06
EV/EBITDA
13.13
EV/Sales
5.75
AMGN's EPS is down by 20% year-on-year and by 19% since the previous quarter
The P/E is 13% below the 5-year quarterly average of 24.8 but 2.5% above the last 4 quarters average of 21.0
The stock's price to book (P/B) is 55% more than its 5-year quarterly average of 9.6
Amgen's equity has decreased by 23% YoY and by 12% from the previous quarter
The P/S is 14% less than the last 4 quarters average of 5.6 and 11% less than the 5-year quarterly average of 5.4
The revenue has grown by 4.9% year-on-year

Efficiency

How efficient is Amgen business performance
The ROIC has contracted by 25% YoY and by 14% from the previous quarter
AMGN's return on assets is down by 23% year-on-year and by 17% since the previous quarter
AMGN's return on sales is down by 23% year-on-year and by 17% since the previous quarter
The ROE has contracted by 15% YoY and by 14% from the previous quarter

Dividends

What is AMGN's dividend history
DPS
$6.88
Dividend yield
3.25%
Payout ratio
69.5%
Recent dividends

Financial health

How did Amgen financials performed over time
Amgen's total assets is 16% more than its total liabilities
AMGN's quick ratio is down by 46% year-on-year and by 26% since the previous quarter
Amgen's current ratio has decreased by 40% YoY and by 21% from the previous quarter
AMGN's debt to equity is up by 24% YoY and by 14% QoQ
Amgen's equity has decreased by 23% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.